title: In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010.
abstract: This study examines in vitro antimicrobial resistance data from Escherichia coli isolates obtained from urine samples of U.S. outpatients between 2000 and 2010 using The Surveillance Network (TSN). Antimicrobial susceptibility results (n = 12,253,679) showed the greatest increases in E. coli resistance from 2000 to 2010 for ciprofloxacin (3% to 17.1%) and trimethoprim-sulfamethoxazole (TMP-SMX) (17.9% to 24.2%), whereas nitrofurantoin (0.8% to 1.6%) and ceftriaxone (0.2% to 2.3%) showed minimal change. From 2000 to 2010, the antimicrobial resistance of urinary E. coli isolates to ciprofloxacin and TMP-SMX among outpatients increased substantially.
authors.affiliation: School of Public Health and Health Services, George Washington University, Washington, DC, USA.
authors.forename: Guillermo V
authors.initials: GV
authors.lastname: Sanchez
authors.forename: Ronald N
authors.initials: RN
authors.lastname: Master
authors.forename: James A
authors.initials: JA
authors.lastname: Karlowsky
authors.forename: Jose M
authors.initials: JM
authors.lastname: Bordon
mesh_terms: D002443:Ceftriaxone / Q000494:pharmacology; D018550:Cephalosporin Resistance; D002939:Ciprofloxacin / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects; D004927:Escherichia coli Infections / Q000453:epidemiology / Q000382:microbiology*; D006801:Humans; D008826:Microbial Sensitivity Tests; D009582:Nitrofurantoin / Q000494:pharmacology; D010045:Outpatients; D011159:Population Surveillance; D014296:Trimethoprim Resistance; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology; D014481:United States; D014552:Urinary Tract Infections / Q000453:epidemiology / Q000382:microbiology*
chemical_list: D002939:Ciprofloxacin; D002443:Ceftriaxone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D009582:Nitrofurantoin